[1] ISKANDER JK, MILLER ER, CHEN RT.The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety[J]. Pediatr Ann, 2004, 33(9): 599-606. [2] WHO. Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII[EB/OL].[2023-03-18]. https://cioms.ch/wp-content/uploads/2018/03/WG8-Signal-Detection.pdf. [3] BRAZETE C, AGUIAR A, FURTADO I, et al.Thrombotic events and COVID-19 vaccines[J]. Int J Tuberc Lung Dis, 2021, 25(9): 701-707. [4] CIOMS. Definition and Application of Terms for Vaccine Pharmacovigilance[EB/OL]. (2012-01-24)[2023-03-18]. https://www.who.int/publications/m/item/9789290360834. [5] KIM M, KIM S, SHIN JY.Post-approval safety monitoring of quadrivalent and bivalent human papillomavirus vaccines based on real-world data from the Korea Adverse Events Reporting System (KAERS)[J]. Clin Drug Investig, 2020, 40(8): 727-735. [6] YE XF, CHENG G, GUO XJ, et al.Masking effect in the process of signal detection of adverse drug reaction[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(1): 33-35. [7] MAIGNEN F, HAUBEN M, HUNG E, et al.Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases[J]. Pharmacoepidemiol Drug Saf, 2014, 23(2): 195-207. [8] PARIENTE A, DIDAILLER M, AVILLACH P, et al.A potential competition bias in the detection of safety signals from spontaneous reporting databases[J]. Pharmacoepidemiol Drug Saf, 2010, 19(11): 1166-1171. [9] HARPAZ R, DUMOUCHEL W, VAN MANEN R, et al.Signaling COVID-19 vaccine adverse events[J]. Drug Saf, 2022, 45(7): 765-780. [10] LEE H, KIM JH, CHOE YJ, et al.Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical bayes geometric mean, and tree-based scan statistic[J]. Vaccines (Basel), 2020, 8(2): 242. [11] KAMATH A, MAITY N, NAYAK MA.Facial paralysis following influenza vaccination: a disproportionality analysis using the vaccine adverse event reporting system database[J]. Clin Drug Investig, 2020, 40(9): 883-889. [12] LEROY Z, BRODER K, MENSCHIK D, et al.Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system[J]. Vaccine, 2012, 30(11): 2020-2023. [13] LIU YT, ZHANG LT, LIN YZ, et al.Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(1): 96-100, 116. [14] YANG QY, SU J, ZHANG X, et al.Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(10): 1141-1147. [15] RAMDANI Y, LARGEAU B, JONVILLE-BERA AP, et al.COVID-19 vaccination as a trigger of IgA vasculitis: a global pharmacovigilance study[J]. J Rheumatol, 2023, 50(4): 564-567. [16] ELAS M, VILLATORO N, PEZZOLI L.Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador[J]. Vaccine, 2021, 39(34): 4849-4855. [17] KIM JE, PARK J, MIN YG, et al.Associations of neuralgic amyotrophy with COVID-19 vaccination: disproportionality analysis using the World Health Organization pharmacovigilance database[J]. Muscle Nerve, 2022, 66(6): 766-770. [18] KIM JE, PARK J, SONG TJ.A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database[J]. Mult Scler, 2022, 28(13): 2112-2123. [19] JEONG HS, CHUN BC.Signal detection of COVID-19 vaccines adverse events using spontaneous reports from South Korea[J]. Pharmacoepidemiol Drug Saf, 2023, 32(9): 961-968. [20] PRONTSKUS V, FRESSE A, YELEHE-OKOUMA M, et al.COVID-19 vaccination and the incidence of de novo or recurrent rheumatoid arthritis: a French and international (VigiBase) signal detection study[J]. Clin Pharmacol Ther, 2023, 113(5): 1107-1116. [21] XIA L, LI K, LI Y, et al.Comparison of statistical signal detection methods in adverse events following immunization - China, 2011-2015[J]. China CDC Wkly, 2024, 6(16): 350-356. [22] BATE A, LINDQUIST M, EDWARDS IR, et al.A Bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol, 1998, 54(4): 315-321. [23] VAN PUIJENBROEK EP, BATE A, LEUFKENS HG, et al.A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10. [24] WHO. Global manual on surveillance of adverse events following immunization[EB/OL]. (2016-05-31)[2023-10-07]. https://www.who.int/publications/i/item /9789241507769. [25] WU WD, LIU DW, LI KL, et al.Analysis on surveillance data of adverse events following immunization in China, 2012[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2014, 20(1): 1-12, 66. [26] YE JK, LI KL, XU DS, et al.Evaluation of the adverse events following immunization information management system in China, 2013[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2015, 21(2): 121-131, 200. [27] CHEN RT, RASTOGI SC, MULLEN JR, et al.The vaccine adverse event reporting system (VAERS)[J]. Vaccine, 1994, 12(6): 542-550. |